| Dupilumab has been approved in several countries for Atopic dermatitis (AD) in patients as young as 6 years |
| Practical management issues around the use of dupilumab for AD remain, including considerations for treatment initiation and maintenance, special populations of interest, and management of potential adverse events |
| A panel of Canadian dermatologists reviews and provides practical recommendations for the use of dupilumab based on available literature and clinical expertise |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.